Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cue Biopharma (CUE) Change in Cash (2017 - 2025)

Historic Change in Cash for Cue Biopharma (CUE) over the last 9 years, with Q3 2025 value amounting to -$15.8 million.

  • Cue Biopharma's Change in Cash fell 76015.89% to -$15.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$20.7 million, marking a year-over-year increase of 696.48%. This contributed to the annual value of -$26.1 million for FY2024, which is 74072.28% down from last year.
  • Latest data reveals that Cue Biopharma reported Change in Cash of -$15.8 million as of Q3 2025, which was down 76015.89% from $14.4 million recorded in Q2 2025.
  • In the past 5 years, Cue Biopharma's Change in Cash registered a high of $21.9 million during Q4 2022, and its lowest value of -$36.4 million during Q3 2022.
  • Moreover, its 5-year median value for Change in Cash was -$3.3 million (2021), whereas its average is -$3.3 million.
  • Per our database at Business Quant, Cue Biopharma's Change in Cash soared by 77093.09% in 2022 and then plummeted by 76015.89% in 2025.
  • Cue Biopharma's Change in Cash (Quarter) stood at -$3.3 million in 2021, then surged by 770.93% to $21.9 million in 2022, then tumbled by 128.22% to -$6.2 million in 2023, then tumbled by 61.29% to -$10.0 million in 2024, then crashed by 58.53% to -$15.8 million in 2025.
  • Its Change in Cash stands at -$15.8 million for Q3 2025, versus $14.4 million for Q2 2025 and -$9.3 million for Q1 2025.